Section
This analysis of over 63,000 US liver transplants reveals that simultaneous liver-kidney transplantation (SLKT) confers significant survival benefit only in patients with severe renal dysfunction (eGFR <30), with no advantage in those wi
TBX2 is identified as a key transcription factor repressing vascular calcification by controlling RUNX2 and the inflammatory NLRP3 pathway, highlighting new therapeutic targets to reduce cardiovascular risk in CKD.
This study reveals how liver-sourced apolipoprotein J worsens diabetic kidney disease by impairing lipid regulation via TFEB pathways, highlighting a novel therapeutic target, MK53, for managing diabetic renal injury.
This study reveals that many patients with primary aldosteronism have inappropriately normal aldosterone levels and shows that modifying the aldosterone-to-renin ratio improves sensitivity in diagnosis without compromising specificity.
This study reveals that liver-secreted apolipoprotein J accumulates in renal tubules, disrupting TFEB-mediated lipid homeostasis and exacerbating diabetic kidney disease, highlighting a novel therapeutic target with the ApoJ antagonist MK53
A risk prediction model derived from the PEXIVAS trial estimates the 2-year relapse probability in ANCA-associated vasculitis, integrating clinical and laboratory factors to improve individualized patient management.
This study elucidates the distinct clinical, pathological, and prognostic differences between native and allograft BK polyomavirus nephropathy, highlighting the severity and poorer outcomes associated with native-kidney BKPyVN and stressing
This national matched cohort study highlights that dual kidney transplantation (DKT) offers improved graft and patient survival compared to single kidney transplantation (SKT) in select recipients, supporting its strategic use for hard-to-p
A 5-year real-world cohort study reveals that declines in CGM-derived time in range correlate with increased microvascular complications in type 1 diabetes, offering prognostic value beyond HbA1c.
A phase 2 randomized trial found that ilofotase alfa did not significantly reduce kidney injury or improve outcomes in high-risk patients undergoing on-pump cardiac surgery, though it was safe and well tolerated.
This study analyzes the epidemiology, treatment processes, and outcomes of critically ill cirrhosis patients undergoing continuous renal replacement therapy, highlighting high mortality rates, anticoagulation practices, and implications of
Following the 2023 US safety net policy for kidney after lung transplantation, a shift from simultaneous lung-kidney transplants to early kidney transplantation post lung transplant was observed, with improved short-term outcomes and reduce
Low-dose rivaroxaban failed to reduce cardiovascular events but increased major bleeding in advanced CKD patients at high cardiovascular risk, underscoring the need for cautious anticoagulant use.
This article reviews over 1100 studies on novel biomarkers for acute kidney injury (AKI) in critically ill patients, highlighting their predictive, diagnostic, and management roles while identifying gaps for future clinical implementation.
KDIGO 2026 updates anemia care in CKD: evidence-based thresholds for iron therapy, preference for IV iron on hemodialysis, ESA-first approach over HIF-PHIs, individualized Hb initiation, and an ESA maintenance upper Hb target <11.5 g/dL.
This article examines the debate on whether RAAS-modifying antihypertensives should be stopped before testing for primary aldosteronism, weighing diagnostic accuracy against patient safety and feasibility.
This article reviews expert perspectives on the efficacy and safety of SGLT inhibitors for cardiovascular and renal disease in type 1 diabetes, outlines translational insights from type 2 diabetes data, and proposes a roadmap for regulatory
Despite identical immunogenetic makeup, half of kidney transplant recipients from identical twins remain on calcineurin inhibitors, with no demonstrable benefit in rejection reduction or graft survival over 25 years, calling for critical re
Finerenone significantly slows kidney function decline and reduces cardiovascular risk in hypertensive non-diabetic CKD patients, with manageable safety profiles, supporting its therapeutic role beyond diabetes.
A 7-day perioperative sofosbuvir/velpatasvir prophylaxis in HCV-positive donor to HCV-negative recipient kidney transplants demonstrated sustained virologic response in over 92% of cases, with favorable 1-year graft survival and function.
